ArticleCancers2021

Evaluating Targeted Therapies in Ovarian Cancer Metabolism: Novel Role for PCSK9 and Second Generation mTOR Inhibitors.

Dafne Jacome Sanz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.